Skip to main content

T-DXd in HER2-Expressing Cancers Regardless of Tumor Location

Intervista a Funda Meric-Bernstam By 5 Giugno 2023No Comments
Congressi

Trastuzumab deruxtecan is an effective treatment option for people with difficult-to-treat HER2-expressing solid tumors, according to the findings of the phase II open-label DESTINY-PanTumor02 trial. At ASCO 2023, in Chicago, we interviewed Funda Meric-Bernstam, chair of the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center and lead author of the study.